Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, Bristol-Myers Squibb Extend Collaboration on Alzheimer's Biomarkers

Premium

Proteomics firm KineMed and Bristol-Myers Squibb have extended their collaboration on Alzheimer's and other neurodegenerative diseases, KineMed said this week.

Under the extension, KineMed will grant BMS a non-exclusive license to its technology for the identification and characterization of Alzheimer's biomarkers in cerebrospinal fluid.

The companies didn't identify what biomarkers they would be investigating, but much of KineMed's past Alzheimer's work has focused on monitoring changes in microtubule dynamics by measuring related CSF biomarkers. The company's platform uses stable isotope labeling with mass spectrometry to measure the rates of change in various disease-related metabolic pathways.

In the June 2010 edition of Neuroscience KineMed scientists published a study tracking turnover levels of the protein tubulin in brain microtubule populations that suggested that changes in microtubule turnover can be used as a biomarker for the synaptic plasticity involved in memory formation.

Financial and other terms of the deal were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more